Morphologic spectrum of immunohistochemically characterized clear cell carcinoma of the ovary: A study of 155 cases

American Journal of Surgical Pathology

Volumn 35, Issue 1, 2011, Pages 36-44

  Delair, Deborah ^a   Oliva, Esther ^b   Köbel, Martin ^c   MacIas, Antonio ^a   Gilks, C Blake ^d   Soslow, Robert A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF CALGARY   (Canada)

Author keywords

clear cell carcinoma; hepatocyte nuclear factor; HNF 1 ; immunohistochemistry; morphology; ovary

Indexed keywords

ESTROGEN RECEPTOR; HEPATOCYTE NUCLEAR FACTOR 1BETA; HNF1B PROTEIN, HUMAN; PROGESTERONE RECEPTOR; PROTEIN P53; TP53 PROTEIN, HUMAN; TUMOR MARKER; WT1 PROTEIN;

ARTICLE; CANADA; CANCER STAGING; CARCINOMA; CELL NUCLEUS; CHEMISTRY; CLINICAL TRIAL; CYTOPLASM; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MITOSIS; MULTICENTER STUDY; OVARY TUMOR; PATHOLOGY; PREDICTIVE VALUE; UNITED STATES;

CANADA; CARCINOMA; CELL NUCLEUS; CYTOPLASM; FEMALE; HEPATOCYTE NUCLEAR FACTOR 1-BETA; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MITOSIS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; UNITED STATES; WT1 PROTEINS;

EID: 78650922763     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e3181ff400e     Document Type: Article

References (22)

1. Crozier M, Copeland L, Silva E, et al. Clear cell carcinoma of the ovary: a study of 59 cases. Gynecol Oncol. 1989;35:199-203.
2. Garg K, Leitao MM Jr, Kauff ND, et al. Selection of endometrial carcinomas for DNA mismatch repair protein immunohistochemistry using patient age and tumor morphology enhances detection of mismatch repair abnormalities. Am J Surg Pathol. 2009;33:925-933.
3. Gilks CB, Inoescu DN, Kalloger SE, et al. Tumor cell type can be reproducibly diagnosed and is of independent prognostic signifi- cance in patients with maximally debulked ovarian carcinoma. Hum Pathol. 2008;39:1239-1251.
4. Goff BA, Sainz de la Cuesta R, Muntz HG, et al. Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol. 1996;60:412-417.
5. Han G, Gilks CB, Leung S, et al. Mixed ovarian epithelial carcinomas with clear cell and serous components are variants of high-grade serous carcinoma: an interobserver correlative and immunohistochemical study of 32 cases. Am J Surg Pathol. 2008;32:955-964.
6. Jensen K, Mariappan R, Putcha G, et al. Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger. Am J Surg Pathol. 2008;32: 1029-1037.
7. Kato N, Sasou S, Motoyama T. Expression of hepatocyte nuclear factor-1beta (HNF-1beta) in clear cell tumors and endometriosis of the ovary. Mod Pathol. 2006;19:83-89.
8. Kobayashi H. Ovarian cancer in endometriosis: epidemiology, natural history, and clinical diagnosis. Int J Clin Oncol. 2009;14:378-382.
9. Kobayashi H, Yamada Y, Kanayama S, et al. The role of hepatocyte nuclear factor-1beta in the pathogenesis of clear cell carcinoma of the ovary. Int J Gynecol Cancer. 2009;19:471-479.
10. Kobel M, Kalloger SE, Carrick J, et al. A limited panel of immunomarkers can reliably distinguish between clear cell and highgrade serous carcinoma of the ovary.AmJ Surg Pathol. 2009;33:14-21.
11. Kuo K, Mao T, Jones S, et al. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J of Pathol. 2009;174: 1597-1601.
12. Miyazawa M, Yasuda M, Fujita M, et al. Therapeutic strategy targeting the mTOR-HIF-1alpha-VEGF pathway in ovarian clear cell adenocarcinoma. Pathol Int. 2009;59:19-27.
13. Nagai Y, Inamine M, Hirakawa M, et al. Postoperative whole abdominal radiotherapy in clear cell adenocarcinoma of the ovary. Gynecol Oncol. 2007;107:469-473.
14. Ohishi Y, Oda Y, Kuihari S, et al. Hobnail-like cells in serous borderline tumor do not represent concomitant incipient clear cell neoplasms. Hum Pathol. 2009;40:1168-1175.
15. Pather S, Quinn MA. Clear cell cancer of the ovaryFis it chemosensitive? Int J Gynecol Cancer. 2005;15:432-437.
16. Pectasides D, Pectasides E, Psyrri A, et al. Treatment issues in clear cell carcinoma of the ovary: a different entity? Oncologist. 2006;11: 1089-1094.
17. Sangoi AR, Soslow RA, Teng NN, et al. Ovarian clear cell carcinoma with papillary features: a potential mimic of serous tumor of low malignant potential. Am J Surg Pathol. 2008;32:269-274.
18. Silva EG, Young RH. Endometrioid neoplasms with clear cells: a report of 21 cases in which the alteration is not of typical secretory type. Am J Surg Pathol. 2007;31:1203-1208.
19. Sugiyama T, Kamura T, Kigawa J, et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer. 2000;88:2584-2589.
20. Tan DSP, Kaye S. Ovarian clear cell adenocarcinoma: a continuing enigma. Am J of Clin Pathol. 2007;60:355-360.
21. Tavasolli FA, Devilee P. World Heath Organization Classification of Tumors. Tumors of the Breast and the Female Genital Organs. Lyon: IARC Press, WHO; 2003.
22. Tsuchiya A, Sakamoto M, Yasuda J, et al. Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol. 2003; 163:2503-2512.